Value Stock Alert: 1 Global Healthcare Company Set to Rise

Bausch Health Companies Inc. (TSX:BHC)(NYSE:BHC) has an established line of products that positions the company to compete in all areas of the eye-health market.

| More on:
healthcare pharma

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Bausch Health Companies (TSX:BHC)(NYSE:BHC) is a global company whose mission is to improve people’s lives with healthcare products. The company develops, manufactures, and markets, primarily in the therapeutic areas of eye-health, gastroenterology (GI) and dermatology, a broad range of branded pharmaceuticals, generic pharmaceuticals, over-the-counter (OTC) products, and medical devices. These are marketed directly or indirectly in approximately 100 countries.

The company’s portfolio of products falls into four operating and reportable segments. The Bausch and Lomb segment focuses on vision care, surgical, and consumer and ophthalmology products. The Salix segment consists of sales of GI products. The ortho-dermatologics segment consists of sales of dermatological products and global sales of Solta medical aesthetic devices. The diversified products segment consists of sales of pharmaceutical products in the areas of neurology and certain other therapeutic classes, and dentistry products.

Global vision care business

The company’s Bausch and Lomb segment includes a global eye-health business and an international medical prescription business. The global Bausch and Lomb eye-health business includes the global vision care, surgical, and consumer and ophthalmology prescription products, which, in aggregate, accounted for approximately 41%, 42%, and 43% of the company’s revenues for 2020, 2019, and 2018, respectively.

Bausch’s international prescription business includes sales in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products and OTC products, which, in aggregate, accounted for approximately 14%, 13%, and 13% of the company’s revenues for 2020, 2019, and 2018, respectively.

Fast-growing eye-health market

Bausch’s global Bausch and Lomb business is a fully integrated eye-health business, which is critical to maintaining and developing the company’s position in the global eye-health market. As a fully integrated eye-health business with a 165-year legacy, Bausch and Lomb has an established line of contact lenses, intraocular lenses, and other medical devices, surgical systems and devices, vitamin and mineral supplements, lens care products, prescription eye-medications, and other consumer products that position the company to compete in all areas of the eye-health market.

As part of the company’s global Bausch and Lomb business strategy, Bausch continually looks for key trends in the eye-health market to meet changing patient needs and identify areas for investment and growth. For instance, one of the trends the company sees is the increasing rate of myopia and, importantly, myopia as a potential risk factor for glaucoma, macular degeneration, and retinal detachment.

Exciting product development

Research indicates an increased demand for new eye-health products that address conditions brought on by factors, such as increased screen time, lack of outdoor activities, and academic pressures, as well as conditions brought on by an aging population. To supplement the well-established Bausch and Lomb product lines, the company continues to identify new products tailored to address key trends, which it develops internally to generate organic growth.

Bausch also licenses selective molecules and technology to leverage the company’s own research expertise through product development. Recent product launches include daily disposable contact lenses, lenses for eye redness treatment, pressure lowering eye drop for patients with angle glaucoma, and vitamins to protect the eye from stressors such as sunlight and blue light emitted from digital devices.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nikhil Kumar has no position in any of the stocks mentioned. Tom Gardner owns shares of Bausch Health Companies. The Motley Fool owns shares of and recommends Bausch Health Companies.

More on Investing

Investing

KM Throwaway Post

Read more »

Investing

Carlos Test Yoast Metadata

Read more »

Investing

KM Ad Test

This is my excerpt.

Read more »

Investing

Test post for affiliate partner mockups

Updated: 9/17/2024. This post was not sponsored. The views and opinions expressed in this review are purely those of the…

Read more »

Investing

Testing Ecap Error

Premium content from Motley Fool Stock Advisor We here at Motley Fool Stock Advisor believe investors should own at least…

Read more »

Investing

TSX Today: Testing the Ad for James

la la la dee dah.

Read more »

Lady holding remote control pointed towards a TV
Investing

2 Streaming Stocks to Buy Now and 1 to Run From

There are streaming stocks on the TSX that are worth paying attention to in 2023 and beyond.

Read more »

A red umbrella stands higher than a crowd of black umbrellas.
Stocks for Beginners

Top Recession-Resilient TSX Stocks to Buy With $3,000

It's time to increase your exposure to defensives!

Read more »